This session is developed and funded by Lilly for UK HCPs and other relevant decision makers.

Join an interactive discussion on how changes in diagnostics are reshaping healthcare delivery in neuroscience and gastroenterology. We will explore the exciting opportunities for how cerebral spinal fluid (CSF) and blood-based biomarkers can support the diagnosis of Alzheimer’s Disease. In a similar vein, we will discuss how intestinal ultrasound as a point-of-care test can accelerate diagnosis and disease assessment for patients suffering with inflammatory bowel disease. These advancements are set to bring system-wide shifts to the diagnostic landscape. The question is: are you ready to uncover the potential benefits evolving diagnostics can offer, in areas such as equitable access, patient experience, and wider system efficiency?

Lilly has provided a sponsorship towards this conference, however, have had no input, control, or influence over the agenda, speaker selections, presentations, or collateral content, except for Lilly organised and funded sessions. Lilly® is a registered trademark of Eli Lilly and Company.

April 2025 | PP-MG-GB-0724